Evidence map›Paper›PMID 41316287›Full record

ArticleMicrobial cell factories2025

Engineering of FK520 polyketide synthase for rapid access to quality control reference standards.

Nina Žigart, Petra Pivk Lukančič, Tjaša Drčar, Jan Peterka, Maja Harej Perko, Peter Mrak

Abstract read
In one paragraph

Article in Microbial cell factories, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Nina ŽigartSandoz Technical Operations, MS&T Antiinfectives, Kolodvorska 27, SI-1234, Mengeš, Slovenia.ORCID http://orcid.org/0000-0001-9388-8616
Petra Pivk LukančičSandoz Technical Operations, MS&T Antiinfectives, Kolodvorska 27, SI-1234, Mengeš, Slovenia.
Tjaša DrčarSandoz Technical Operations, MS&T Antiinfectives, Kolodvorska 27, SI-1234, Mengeš, Slovenia.
Jan PeterkaSandoz Technical Operations, MS&T Antiinfectives, Kolodvorska 27, SI-1234, Mengeš, Slovenia.
Maja Harej PerkoSandoz Development Center Slovenia, Ljubljana, Slovenia.
Peter MrakSandoz Technical Operations, MS&T Antiinfectives, Kolodvorska 27, SI-1234, Mengeš, Slovenia. peter.mrak@sandoz.com.ORCID http://orcid.org/0000-0001-7820-9355

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Despite the ability of mega synthases to construct complex structures with high precision, the main product is often accompanied by minor congeners because of relaxed selectivity of biosynthetic steps. In the case of polyketides, these may arise from promiscuity of acyltransferase domains while selecting the extender building blocks. This yields compounds which can differ only slightly from the main product and are therefore notoriously difficult to separate. For compounds in medicinal use, such congeners are considered impurities and must be precisely quantified in commercial production through use of reference standards. The immunosuppressants FK506, FK520, and its chlorinated derivate pimecrolimus, are well known for accumulation of minor congeners in the fermentation, which demands costly and lengthy purification with industrial HPLC to obtain material of sufficient purity. The relaxed selectivity of the AT domain in module 4 of FK506/520 PKS results in production of FK506, FK506D, FK520, and FK523 from the same system. Here, we investigate additional minor impurities, specifically the 11-, 17-, and 19-ethyl FK520 derivatives. Because the PKS can process these analogues to completion, it is reasonable to expect that strategic replacement of AT domains in modules 9, 6, and 5 (respectively), would enhance their production. Indeed, we show a direct, exclusive and high titer biosynthesis of these analogues through PKS engineering, replacing tedious and costly isolation by preparative HPLC and significantly improving access to these minor congeners. In addition, by using the AT4 as the donor domain, an interesting system is obtained, containing identical promiscuous AT domains at two different positions, and consequently distinct intra- and intermodular context. Media-dependent extender pool modulation toward methylmalonyl-CoA showed unexpected but consistent distribution of the four predicted analogues for each of the engineered systems. Despite the use of identical ATs, extender incorporation preference is different, depending on the modular context. It appears that the selectivity of the downstream AT4-containing module depends on the structural features of the incoming acyl chain; features installed by a module well upstream in the assembly line. Therefore, the global context of the PKS may be more impactful to the outcome of AT-engineering experiments than is generally considered.

Indexed as

Polyketide SynthasesProtein EngineeringTacrolimusChromatography, High Pressure LiquidMetabolic EngineeringQuality ControlReference StandardsPolyketide SynthasesTacrolimusAnaloguesAscomycinAT domainChlorinationFK506FK520ImpurityIsoleucinePimecrolimusPKS engineeringRelated compoundsTacrolimusValine

Identifiers

PMID41316287
PMCPMC12664185

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.